Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00828841 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Phase 2 study, sponsored by Accelerated Community Oncology Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 601
- Enrollment target
NCT00828841: Completed Phase 2 study, sponsored by Accelerated Community Oncology Research Network.
NCT00828841 is a Phase 2 study that has completed, run by Accelerated Community Oncology Research Network. The registered enrollment target is 601 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (352% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00828841, a Phase 2 study, has completed, sponsored by Accelerated Community Oncology Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 601 participants
- Enrollment target
Study Summary
This study is testing the investigational drug, cetuximab, in combination with different chemotherapy drugs for lung cancer. The aim of the study is to determine which of the drug combinations looks most promising and should be tested further. The study will also look at what side effects may occur.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Paclitaxel
- DRUG Cetuximab
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 601 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
What the finished NCT00828841 record still lists
NCT00828841 is an interventional study that assigns participants to a tested intervention. The registered 601 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (352% higher).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT00828841 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00828841 about?
NCT00828841 is a clinical study titled "Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC". This study is testing the investigational drug, cetuximab, in combination with different chemotherapy drugs for lung cancer. The aim of the study is to determine which of the drug combinations looks most promising and should be tested further. The study will also look at what side effects may occur.
What is the current status of trial NCT00828841?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 601 participants. The study started on 2008-12. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00828841?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Paclitaxel (DRUG), Cetuximab (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00828841?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00828841's enrollment target sits among peer trials
601 53rd of 2000 higher than 1,948 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia